

Two-year data for Novartis brolocizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Oct 27, 2018

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd-0>